Signal from the log
AnaCardio
$70.9M
AnaCardio, à Stockholm, développe AC01, un médicament oral qui renforce la contraction du cœur dans l'insuffisance cardiaque à fraction d'éjection réduite. La presse annonce une série B de 62,5 M€ co-menée par Novo Holdings pour un essai de phase IIb ; aucun communiqué de la société n'était en ligne au relevé.
Spotted Amount read from the headline
Announced on , logged by the watch of 29 September 2026.
- Operation
- Funding round
- Announced amount
- $70.9M
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
What is missing before publishing
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
- The amount shown is an automatic reading of the source headline, not a reading of the press release. It is not verified yet.
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source endpoints
Logged on 29 September 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.